Speakers

Daniel Álvarez currently leads the international development activities of BIOGA – the Galicia Life Sciences and Biotechnology Cluster. Holding a PhD in Biology with a specialisation in Biotechnology from the University of Freiburg (Germany), as well as postgraduate business training in management and biotechnology business administration, he combines scientific expertise with experience in innovation, internationalisation, and ecosystem development.

Throughout his career, Daniel has worked across research institutions, international organisations, and innovation clusters in Europe and the Americas, contributing to collaborative initiatives in biotechnology, health innovation, food systems, and sustainability. His work includes the coordination of collaborative R&D and innovation projects, the development of international partnerships and innovation ecosystems, support for company internationalisation, and the mobilisation of public and private funding to foster growth and collaboration within the life sciences sector.

https://www.linkedin.com/in/danielalvarezphd/ 

Michael joined Venture Investments in November 2020. 

From 2006-2020, Michael was employed at Genmab in various positions with increasing responsibility; starting in Project Management taking daratumumab / DARZALEX® into the clinic. Between 2010-2018 he led Clinical Development and was part of the senior leadership team that repositioned and rebuilt the company into a global cancer and antibody powerhouse. From 2018 he led R&D Operations preparing the company for filing of its first own product. Prior to Genmab, Michael worked as Associate at BankInvest Biomedical Venture and as Licensing Associate in Scientific Licensing at Novo Nordisk A/S, after having spent 7 years as Research Scientist at Novo Nordisk A/S covering areas such as endocrinology, metabolic disease, cancer and inflammation. 

Before joining the industry, Michael worked for 6 years at the Research Centre for Developmental Medicine & Biology at the University of Auckland, New Zealand, investigating causes and possible treatment modalities of intra-uterine growth restriction. 

Michael earned a Masters (Dipl. Ing. agr.) in Agricultural Science from the University of Stuttgart-Hohenheim, Germany and a Ph.D. in Agricultural Science – summa cum laude – from the University of Göttingen, Germany. 

Christoph Broja is a Partner in the EQT Life Sciences team since 2022.

Prior to joining EQT, Christoph was a Principal in the investment team at Gurnet Point Capital based in Boston, where he was involved in a number of investments in biopharma, medical devices, and molecular diagnostics. Prior to that, Christoph worked at B-Flexion Capital in London.

Christoph started his career as investment analyst at private equity firm Franz Haniel & Cie. in Germany. He holds a degree in Business Administration and is a CFA Charterholder.

 https://www.linkedin.com/in/christoph-broja-2420b81b7/ 

Prof. Dr. Thomas Brück
Technical University of Munich
(*1972) obtained his B.Sc.in Chemistry, Biochemistry and Management Science from Keele University, Stoke on Trent, U.K.. Additionally, he holds an M.Sc. in Molecular Medicine from the same institution. In 2002, Thomas obtained his Ph.D. in Protein Biochemistry from Imperial College and Greenwich University, London, U.K.. From 2002-2006 Dr. Brück held an Assistance Professorship in Marine Proteomics and Biocatalysis at the Center of Excellence for Marine Biotechnology and Biomedicine at Florida Atlantic University (Boca Raton, U.S.A.), focusing on bioactive natural product biosynthesis in marine macroorganisms. In 2006 Thomas Brück returned to Germany and joined Süd-Chemie AG (now Clariant Produkte Deutschland GmbH), where he held various management positions in the central R&D unit Biotechnology. Since 2011 Thomas Brück is a tenured full Professur at the Technical University of Munich (TUM), Germany. He holds the Werner Siemens Chair of Synthetic Biotechnology and is Director of the TUM AlgaeTech Center. The research activities of his Chair are focused around the isolation and development of sustainable biocatalytic processes, that enable conversion of greenhouse gases and biogenic residue streams into value adding products for the food, chemical and pharmaceutical industry sector. Prof. Brück is the current Vice Dean Research and Innovation of the TUM School of Natural Sciences and a member of the German Academy of Technical Sciences, where he advises the German Government.

Petra is Venture Creation & Co-Lead of MAxL at BioM, the cluster organization for Bavaria’s biotechnology industry. She has been part of BioM since 2007, where she co-built the organization’s founder and start-up support activities and supports early-stage life science ventures.

In 2023, she took on the co-lead of MAxL (Munich Accelerator for Life Sciences and Medicine), BioM’s incubator dedicated to pre-seed and early-stage teams.

Petra holds a PhD in biochemistry and has a background in research and industry, with experience in pharma, healthcare and biotech start-ups in both the US and Germany. 

https://www.linkedin.com/in/petraburgstaller/

Henry is a Managing Director in the Global Healthcare Investment Banking team at J.P. Morgan, based in London. Henry leads coverage of BioPharma in EMEA covering everything from major pharma, mid-cap and specialty pharma and biotech. Prior to his role in Healthcare Henry focused on M&A in the UK between 2013-2019 where he helped to lead a number of the most significant public and private transactions across all deal types. Henry studied History at the University of Edinburgh.

Dr. Caroline Corbett; PhD in Epidemiology has over ten years of experience leading cross-sectoral public health and life science projects across academia, industry, and international organizations. Currently the International Network & Projects Management at BioM.

https://www.linkedin.com/in/caroline-corbett-phd-835274a9/ 

Hendrik Dietz is a professor and entrepreneur. He co-founded CPTx in 2021 to carry forward 15 years of foundational research of single stranded DNA technologies and biomolecular design from nucleic acids to proteins at TUM. Dietz has published over 100 original research articles, many of which in high-ranking journals such as Nature and Science, and is recipient of numerous honors and awards, including the Gottfried Wilhelm Leibniz Prize, the highest German scientific distinction. He received a PhD from TUM and held positions at Harvard Medical School / Dana Farber Cancer Institute before becoming a professor at TUM. Committed to transforming foundational discoveries into real-world therapies, at CPTx he has assembled the talent and infrastructure needed for translating foundational discoveries into new genetic medicines.

Prof. Dr. Ali Maximilian Ertürk is Director at Helmholtz Munich and Professor at Ludwig Maximilian University of Munich. He is the founder and CEO of Deep Piction, a company pioneering whole-body, cell-level imaging combined with AI to transform disease understanding and accelerate drug development.

His work focuses on developing technologies that enable the visualization and analysis of intact biological systems at single-cell resolution, bridging the gap between fundamental research and therapeutic innovation. His research has been published in leading journals including Cell, Nature, Nature and Biotechnology, and he is actively driving the translation of advanced imaging and AI into precision medicine applications.

www.linkedin.com/in/ali-maximilian-ert%C3%BCrk/

Dr. med. Anna Fleischer is a clinician scientist at the University Hospital Würzburg and the inventor and project lead of ENDOLEASE. Her work focuses on translational medical technology, precision drug delivery, psycho-oncology, and the development of innovative platform technologies for severe diseases. With ENDOLEASE, she and her interdisciplinary team are developing a bioresorbable intra-arterial drug delivery system designed to enable localized, controlled therapeutic release directly into the arterial supply of target tissues.

Dr. Oliver Goldenberg is a biotechnology executive with over two decades of experience driving commercial growth and innovation in the European life sciences sector. He currently serves in a senior commercial leadership role at Roche Diagnostics. His technical expertise centers on genomics, Next-Generation Sequencing (NGS), and molecular diagnostics.

https://www.linkedin.com/in/oliver-goldenberg-7a53152/ 

Elisabeth Harbich joined BioM in January 2025 as a project manager in Start-up Support. She is involved in start-up activities at BioM like mentoring programs, bootcamps, and pitching events.

Elisabeth studied bioengineering (Munich University of Applied Sciences) and biochemistry (LMU Munich). She previously worked in process development at Micromet/Amgen, coordinating cell line development, generating monoclonal eukaryotic antibodies, and preparing regulatory documentation for clinical trial submissions, including managing an external service provider.

www.linkedin.com/in/elisabeth-harbich-scientist-projectmanager-startup-support/

Professor Michael Hoelscher is an infectious disease physician and Director of the Tropical Institute at the University of Munich, and he also leads the Fraunhofer site for Immunology, Infection and Pandemic Research in Munich-Penzberg. In 1996, he founded the Mbeya Medical Research Center, which has since become one of Africa’s leading clinical research institutions.

At the Tropical Institute, the first SARS‑CoV‑2 case in Germany was diagnosed, and Professor Hoelscher subsequently was involved in multiple epidemiological and clinical COVID‑19 studies. In December 2020, he was invited to support the establishment of a pandemic research institute hosted by the Fraunhofer Gesellschaft.

His research focuses on the development of novel strategies to prevent, diagnose, and treat HIV, tuberculosis, and emerging infectious diseases, with a strong emphasis on translation from basic research to clinical trials and public health implementation. He has contributed to more than 50 multinational studies. Under his leadership, LMU Klinikum is developing a novel tuberculosis drug that is now entering Phase III licensing trials.

Prof. Hrabě de Angelis’ areas of research include genetics, diabetes, phenotyping and data mining.

Martin Hrabě de Angelis studied biology at Philipps University in Marburg and completed his PhD on the influence of growth factors on early embryonic development in 1994. During his time as a postdoctoral researcher (1994 – 1997) at the internationally recognized Jackson Laboratory in Bar Harbor (USA), he examined the Delta/Notch signaling pathway and somitogenesis in mouse models. Deciphering the genetic underpinning for pattern formation of the body axis has been a major focus. Already at that time modelling human health and disease has been of major interest.

In 1997 he returned to Germany and headed the working group “Functional Genetics” at the Institute for Mammalian Genetics GSF, Munich. Together with Prof. Rudi Balling and colleagues he successfully performed the first comprehensive ENU-mutagenesis screen for disease models, resulting in great many new models, which have been used in the own laboratory and world-wide. 

In 2001, Martin founded the world first Mouse Clinic (German Mouse Clinic) for the systemic analysis of mouse models for human disease including a special focus on metabolism. This was possible in his new position as director of the Institute of Experimental Genetics at Helmholtz Munich (German Research Center for Environmental Health). In 2003, he was appointed to the Chair of Experimental Genetics at Technical University Munich. He served as founding director of the European research consortium "INFRAFRONTIER ERIC" and is now on the supervisory board / Assembly of members states.

Hrabě de Angelis and colleagues have shown that dietary obesity and diabetes mellitus can be epigenetically inherited from the offspring via egg cells as well as sperm. By studying knockout mice, each of which lacked a precisely selected gene, he succeeded in identifying 51 unknown genes that could play an important role in the development of metabolic diseases and diabetes. His published research articles, have been cited over 52 000 times. Martin Hrabě de Angelis directs national and international research projects. He is co-founder and board member of the German Center for Diabetes Research (DZD, 2009). He is also elected member of the National Academy of Science (Leopoldina), Member and Spokesperson of the Executive Board (acting), Research Director Helmholtz Munich, Full Professor and Chair of Experimental Genetics Technical University Munich Germany, Director of the Institute of Experimental Genetics Helmholtz Munich.

Dmitrij Hristodorov is General Partner at Forbion. His current portfolio covers various stages, treatment modalities and disease areas. To date, he serves as a board member for Progentos, RyCarma, Complement, Seamless, AAVantgarde, Kynexis, Beacon, and Mosanna. He previously served as a board observer of VectorY Therapeutics, as a board observer and R&D committee member of Gyroscope Therapeutics that was acquired for up to $1.5Bn by Novartis in December 2021, as a board director of Rampart Bio, and as a board director of Oxular that was acquired by Regeneron in 2025.

Before joining Forbion, he held roles in R&D Ophthalmology and Business Development at Bayer Pharma.

In 2013 he received his PhD degree summa cum laude from the University of Aachen (RWTH) for the work he performed at Fraunhofer Institute in immunology.

https://www.linkedin.com/in/dr-dmitrij-hristodorov-b8896080/

Prof. Dr. med. Dr. h.c. Ralf Huss

Managing Director of Bio^M Biotech Development GmbH and spokesperson for the Bavarian Biotechnology Cluster

Ralf Huss completed his medical studies with a doctorate in immunology at Friedrich-Alexander University (FAU) in Erlangen-Nuremberg. After research stays in Zurich (Switzerland) and Seattle (USA), he became a specialist in pathology and adjunct professor at Ludwig Maximilian University (LMU) in Munich; at the same time, he was an honorary professor at University College Dublin (Ireland) and finally a lecturer in biomaterials at the Faculty of Chemistry (School of Natural Sciences) at the Technical University of Munich (TUM). After working for Roche and small to medium-sized companies in the field of biotechnology and digital diagnostics, his focus as a visiting professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine in Winston-Salem (USA) was on topics related to regenerative medicine and the use of genetically modified stem cells in the treatment of numerous diseases. In recent years, his research interests have increasingly expanded to include the application of data and AI in clinical and biopharmaceutical research and the entire field of ‘digital medicine’. He is a member of numerous national and international professional associations, advisory boards and curatorial boards.

On 1 January 2023, Prof. Huss took over as managing director of BioM Biotech Cluster Development GmbH, which has been the network organisation for the biotechnology industry in Munich and Bavaria since 1997.

Dr. med. Kai Joachimsen, MD, MBA
General Manager BPI e.V.

Licensed and PhD-qualified physician as well as a certified business economist.
He completed his medical studies in Marburg, Münster, and Vienna. His experimental doctoral thesis was in radiology and cardiology (magnetic resonance imaging in cardiomyopathies).
He received his Master of Business Administration (MBA) from Northwestern University Kellogg in Chicago and WHU in Vallendar.
He held senior positions in the pharmaceutical industry at GlaxoWellcome/GSK as Head of Marketing & Business Team Respiratory, was Head of Respiratory & Cardiovascular at Boehringer Ingelheim, and also served as Business Unit Leader, Head of New Commercial Model, EMEAC Franchise Leader, and Global Franchise Leader at MSD/Merck Inc. in Munich and New Jersey. In 2012, he took over the sole management of Chiesi GmbH Germany and additionally as CEO in the private equity sector.
Since 2018, he has been with BPI e.V. and since 2019, he has been serving as Chief Executive Officer and member of the board.

Prof. Dr. Simon N. Jacob
Technical University of Munich, TUM School of Medicine and Health

Prof. Jacob (b. 1977) is a neurologist and neurophysiologist. His research focusses on the cellular and circuit basis of cognitive brain functions. Based on his experimental work, Prof. Jacob is developing technologies that can contribute to improving treatments for disorders in the domains of perception, memory and language.

Prof. Jacob studied medicine in Freiburg and Heidelberg, at University College London (UK) and at Harvard University (USA) as a fellow of the German National Academic Foundation. He obtained his medical doctorate degree in 2006 based on experimental neurophysiological work conducted at Yale University (USA). Prof. Jacob was a postdoctoral researcher at the Center for Integrative Neuroscience in Tübingen and qualified as a board-certified neurologist after training in Tübingen and at the Charité in Berlin. In 2015, Prof. Jacob moved to TUM where he established an interdisciplinary research group investigating the neuronal mechanisms of cognitive brain functions. He was appointed professor for Translational Neurotechnology in 2019.

Awards

• ERC Consolidator Grant (2024)
• Early Excellence Academy, SyNergy Cluster for Systems Neurology (2023)
• Speaker TUM Innovation Network NEUROTECH (2021-2026)
• ERC Starting Grant (2017)
• Charité Clinical Scientist Award (2014)

Dr. Ahmed Khalifa is a seasoned physician and medical executive with nearly 20 years of experience in the pharmaceutical industry. As the Country Medical Director at MSD Sharp & Dohme GmbH in Germany, he leads the Medical Affairs team in advancing the company’s mission to save and improve lives through innovative healthcare solutions. In this role, Dr. Khalifa oversees the development and execution of the medical strategy, generates clinical insights to inform global programs, and manages the medical aspects of HTA submissions to enhance patient access to MSD’s portfolio of medicines and vaccines. Trained as a medical doctor and gastroenterologist, Dr. Khalifa has held various roles in clinical development and medical affairs, and has authored numerous publications in Gastroenterology and Rheumatology.

https://www.linkedin.com/in/ahmed-khalifa-md-a309b71a/ 

Dr. biol. hum. Carolin Kinzel, M.Sc., B.A. (34 Jahre) ist Bereichsleitung für das Thema Innovationstransfer sowie Qualitätsmanagementbeauftragte am Institut für Digitale Medizin (IDM) – zugehörig zum Universitätsklinikum Augsburg. Zu ihren Hauptaufgaben zählt neben dem Aufbau des medizinisch digitalen Innovationshubs in Augsburg (MeDIHA) auch die Verantwortung der Zertifizierungsprozesse im IDM.

Uli Kinzel is a Managing Director and Head of Healthcare at Fortlane Partners, a leading European advisory firm specialising in strategy, M&A and transformation. Uli holds an MBA from Ludwig Maximilian University in Munich and has around 30 years of M&A experience, including 25 years focused on healthcare. He has advised on more than 60 financing and M&A transactions, including the sale of Merck Consumer Health to Procter & Gamble, the acquisition of global rights to a neuroblastoma product for EUSA Pharma, and the strategic collaboration of Autolus with BioNTech in CAR-T. Prior to his current role, he worked at Stifel, goetzpartners, and Nomura, and was a founding partner at Code Securities Ltd.

https://www.linkedin.com/in/uli-kinzel-99308420/

Ulrike Köhl is a full Professor for Immune Oncology and director of the Institute for Clinical Immunology at the University of Leipzig, Germany as well as the director of the Fraunhofer Institute for Cell Therapy and Immunology since 2017. She held a position of a full Professor and director of the Institute of Cellular Therapeutics at Hannover Medical School from 2012 to 2023.

She holds a degree in biology supplemented by a medicine study, received her PhD in 1995. She worked at the MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany.

She is an international leading expert in the development and manufacturing of cell and gene therapies in cancer and regenerative medicine and collaborates with both international industry and academic partners. She has a specific own research focus on primary human NK cells as well as chimeric antigen receptor (CAR) expressing T and NK effector cells. The Köhl team has been responsible for one of the first NK cell trial in Europe. Prof. Köhl’s work encompasses a wide range of ATMPs, including CAR T cells and antigen-specific T cells. In that, she actively contributes to the harmonization of manufacturing and quality control standards for cell-based therapies.

Currently, Prof. Köhl is heading “SaxoCell”, a cluster for cell and gene therapy, funded by the Germany federal government as a future and excellence initiative. Furthermore, Ulrike Köhl has extensive experience in leading EU consortia and is currently involved in several EU projects.

Prof. Köhl is a member of numerous national and international societies and serves as a reviewer for various authorities as well as for several journals and foundations. She is a committee member of scientific advisory boards of different companies. In 2023, Prof. Köhl was appointed as a member of the Saxon Academy of Sciences and Humanities in Leipzig.

https://de.linkedin.com/in/ulrike-köhl-a485b7132 

Susanne Kreutz is the Global Head of Corporate & Business Development. She held various other positions at Novartis since she joined in 2019, including Head of Business Development & Licensing for Oncology and Global Head of Mergers & Acquisitions. 

Susanne has close to 20 years of deep and broad transactional experience in BD&L and M&A gained in the pharmaceutical industry across various therapeutic areas. Prior to joining Novartis, she had an impactful career at Bayer, where she worked in local, regional, and global functions of increasing responsibility in both the commercial organization, as well as M&A and BD&L. 

Susanne is a pharmacist by training and holds a Doctorate degree in Neuropharmacology from the Goethe University in Frankfurt.

https://www.linkedin.com/in/susanne-kreutz-124b54a2/ 

Olivier Litzka has served since 2006 as a partner at Andera Partners, a venture capital and private equity firm based in Paris with offices in Munich, Antwerp, Madrid and Milano. Together with his colleagues, he developed out of Paris the Andera Life Sciences activity to one of the major funds in Europe supporting entrepreneurs and companies in the biopharmaceutical and medical device space, before he opened the office in Munich in 2021.

He started his business career in 1998 with Mercer Management Consulting before joining 3i Group plc in 2000 with a focus on biopharma and medtech investments. 

Olivier Litzka currently serves on the boards of several European and US life sciences companies and was instrumental in the support of many startups up until their respective acquisitions and/or IPOs. 

Olivier Litzka has a Ph.D. in molecular microbiology from the Institut für Genetik und Mikrobiologie in Munich, LMU.

www.linkedin.com/in/olivier-litzka-bb1200

Matthias Meergans, MD, PhD, MSc.

• Executive Director, Research and Development at Association of Research-Based Pharmaceutical Companies (vfa)
• 20 years of experience in global pharmaceutical companies across Medicine, R&D, and Marketing, holding local and international roles.
• Lecturer at the Goethe Business School/Frankfurt (Pharma MBA)
• Board Certificate in Internal Medicine; Master of Science (MSc) in Pharmaceutical Medicine
• Studied Medicine in Berlin and Tübingen

Dr. Thomas Meins is Managing Director of Munich-based Crelux, a subsidiary of WuXi AppTec, a leading global contract research, development and manufacturing organization (CRDMO). With more than 20 years of experience in the life sciences industry, he brings perspectives on how globally integrated research, development and manufacturing capabilities, scientific expertise, and critical infrastructure can accelerate innovation, scale rapidly when needed, and strengthen resilience in the face of global health challenges.

Olivia Merkel has been a Professor of Drug Delivery at LMU Munich since 2015, Chair since 2022, and Vice-Director of the Department of Pharmacy since 2024. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant, and ERC Consolidator Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the co-spokesperson for the BMBF Future Cluster CNAT-M and an author of over 150 articles and book chapters. She served as NIH reviewer from 2014-2015, SNSF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, Associate Editor for DDTR and WIREs Nanomedicine and Nanobiotechnology, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022, and currently is a scientific advisory board member of Coriolis Pharma, AMW, and Corden Pharma as well as a co-founder of RNhale. Her research focuses mainly on RNA formulation and pulmonary delivery for the treatment of a variety of lung diseases.

Dr. Christoph Mittendorf leads Customer Engineering for Google Cloud AI across the DACH region, driving both innovation and customer success with transformative AI. At Google since 2018, he has significantly advanced key technologies underpinning large language models, including TensorFlow, Tokenizers, and Vector Search. Christoph, who holds a Ph.D. from Goethe University Frankfurt with research into electronic markets and artificial general intelligence. Beyond his professional life, he is an avid chess player, ultra-trail runner, and triathlete.

https://www.linkedin.com/in/dr-christoph-mittendorf/

Simon Moroney 

is currently Vice-chair of Novartis AG and Chair of the Belgian AgTech company Biotalys. Until 2019 he was CEO of MorphoSys AG, having co-founded the company in 1992. From 1984-86 he worked for ImmunoGen Inc in Boston. Prior to starting his career in the industry he held academic positions at the University of Cambridge, UK, the ETH Zurich, Switzerland and University of British Columbia, Canada. He obtained his D.Phil in chemistry from the University of Oxford on a Commonwealth Scholarship and his M.Sc in his native New Zealand.

He has received numerous rewards for his services to the biotechnology industry including the Bundesverdienstkreuz am Bande (2004), New Zealand’s World Class New Zealand Award for Biotechnology (2006), and State Medal for Outstanding Services to the Bavarian Economy (2009) and the Most Significant Contribution to the Mediscience Sector; European Mediscience Awards, (2019).

Karl Naegler is a Partner in the Sofinnova Capital Strategy. He joined us in September 2024, bringing a strong track record of 20 years of investment experience.

Before joining Sofinnova, he was a Managing Partner at Wellington Partners Life Sciences and before that, a Partner at Gimv. In those roles, he was instrumental in the success of several high-profile startups, from company formation to exit. These include Seamless Therapeutics, launched with a top syndicate of investors; Breath Therapeutics, a co-investment with Sofinnova, acquired by Zambon; Covagen, acquired by Johnson & Johnson, and Prosonix, acquired by Circassia Pharmaceuticals.

“Sofinnova is a world-class firm that truly leads life sciences venture capital in Europe. The opportunity to be part of an investment platform spanning multiple sectors, stages and geographies, with such a high-caliber team, was an opportunity I could not pass up. I look forward to bringing my experience to bear as we build and support the most innovative companies in life sciences across Europe.”

His career also includes key roles at Ventech and Atlas Venture. Karl earned his PhD in Molecular Neurobiology from the Max-Delbrück-Center for Molecular Medicine in Berlin followed by a position as Scientific Fellow at CNRS for Neurochemistry in Strasbourg.

https://www.linkedin.com/in/karl-naegler-b113151/ 

Dr. Jörg Radtke has been Managing Director of Servier Forschung und Pharma-Entwicklung GmbH since January 2025. He joined Servier in November 2002 as a Clinical Research Associate andsubsequently held positions as a Clinical Trials Project Manager and, from 2011, as Head of Clinical Operations for the DACH region and Benelux. Following an 18-month assignment in Worldwide Regulatory Affairs, he is now responsible for coordinating clinical research activities across Germany, Austria, and Switzerland. Prior to joining Servier, he spent six years as a research associate at the Chair of Nutrition at TUM Weihenstephan.
www.linkedin.com/in/dr-jörg-radtke

Hagen Richter is Head of Innovation for BioPharma at WACKER Chemie AG, based in Munich, Germany. In this role, he is responsible for shaping and advancing WACKER’s innovation strategy in biopharmaceuticals, with a strong focus on collaboration, strategic partnerships, and technology translation. He actively builds and manages partnerships with biotech companies, academic institutions, and industry stakeholders across the life sciences ecosystem. Hagen Richter regularly acts as a speaker and moderator at international biotech conferences, fostering dialogue between science, innovation, and business.

Carsten Rudolph, CEO and co-founder of Ethris, pharmacist by training, received his PhD from the Department of Pharmacy of the FU Berlin. His deep expertise is delivering mRNA specifically to the lungs. He is lead inventor of the SNIM® RNA-Technology and co-inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten Rudolph received his post-doctoral lecture qualification at the Department of Pharmacy, FU Berlin in 2009.

https://www.linkedin.com/in/carsten-rudolph-dr-24b66b1a/ 

Michael Sahnau is responsible for digital transformation in the healthcare sector as Director Healthcare & Life Sciences at Microsoft Deutschland GmbH. With more than 25 years of experience in the IT industry, he has contributed to the introduction of innovative solutions at companies such as Siemens, Philips, and Microsoft. His professional background is characterized by the implementation of new technologies and the leadership of strategic digital transformation initiatives in healthcare.

https://www.linkedin.com/in/sahnau/ 

June 2015 – Aug. 2016: Project Manager New Digital Data- and Business Models (BMW)
Sept. 2016 – today: Founder, Managing Partner (inveox)

Sept. 2020 – today: Member of the Advisory Board (TUM School of Management)
Nov. 2024 – today: Managing Director TUM Venture Lab Healthcare)

https://www.linkedin.com/in/maria-sievert/

Philip Tinnefeld is Director of the Department of Chemistry and Chair of Physical Chemistry at LMU Munich. He leads an interdisciplinary research group in the fields of super-resolution microscopy, DNA nanotechnology, and biosensor technology with a focus on method development. More recently, he has combined single-molecule detection with DNA nanotechnology to develop self-assembling functional components, biosensors, and nanorobots. In addition to more than 200 peer-reviewed publications, he is involved in 12 patent applications and is the initiator of GATTAquant, the first company for applications of DNA origami technology.

linkedin.com/in/philip-tinnefeld-476242170

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

www.linkedin.com/in/angelikavlachou/

Sandra von Meier currently leads Business Development for Life Sciences at Terra Quantum, an innovative AI-driven company focused on drug discovery.

Previously, she served as Head of Business Development and Project Management at Desitin, a neurology and rare disease company, where she was responsible for all business development deals and cross-functional projects across the organization.

Before joining Desitin, Sandra was Head of Business Development and Licensing at Debiopharm, overseeing all in-licensing and out-licensing activities. During her tenure, she led several high-profile transactions, including the in-licensing of a USP inhibitor from Novo Nordisk/Forma, a multi-asset partnership with SunRock and Genome to develop novel antibody–drug conjugates (ADCs) for Debiopharm’s oncology pipeline, as well as clinical collaborations with Repare and Gilead. Her most recent public transaction at Debiopharm was the out-licensing of a radiopharmaceutical asset to ITM.

Prior to Debiopharm, Sandra was Senior Director Business Development & Licensing at Bayer, where she was responsible for oncology asset search, evaluation, and transactions, including the M&A transaction with Vividion Therapeutics. Before that, as Director Business Development Oncology at Merck KGaA, she led numerous strategic transactions, including the collaboration on Xevinapant, partnerships with F-star (bispecific antibodies), Vertex (DDR portfolio), and Pfizer for Bavencio (avelumab).

Sandra began her career at Medigene, a publicly listed German biotechnology company, where she closed several transactions, including the commercialization agreement with Astellas for Eligard.

I hold a PhD in Chemistry from the University of Tübingen and a postgraduate degree in Economics, earning the title of Diplom-Wirtschaftschemiker. After completing my doctoral studies, I began my career at a biotech start-up specializing in drug delivery technologies. In 2001, I moved from the start-up sector to the investment sector and joined Bayern Kapital GmbH. While I was initially responsible for investments across various industries and at various stages of development, I now serve as Director Life Sciences, focusing on investments in innovative Life Science start-ups from the seed to scale-up stages.

Dr. Annette Witzleben is a Partner in Deal Advisory – Valuation at KPMG AG Wirtschaftsprüfungsgesellschaft, based in Munich. She joined KPMG in 2013 and has built deep expertise in business and asset valuations for transaction, tax and legal purposes. Her sector focus lies on Life Science, covering both pre-deal advisory and post-deal services. She also brings extensive experience in strategic planning, financial modelling and business planning. Annette holds a PhD in Business Administration, a Diplom-Kauffrau (MBA-equivalent) and a Master of Business Research from the University of Munich, and is a certified German Tax Accountant (Steuerberaterin).

Dr. Alissa Zeller studied chemistry and material science at the TUM and in Heidelberg. She holds a postdoc in Bioethics from Max-Planck and is a patent attorney.
She leads BASF’s global Intellectual Property and Regulatory organization with global responsibility for patents, trademarks, collaboration agreements, IP‑related M&A, and litigation. She also serves as Chair of the BDI Committee on Intellectual Property and Copyright.

www.linkedin.com/in/alissa-zeller-363844b